Chronic Kidney Disease
–
Early Multiplex Detection of Chronic Kidney Disease
Early Multiplex Detection of Chronic Kidney Disease from a Single Sample
- Simultaneous and quantitative detection of multiple serum biomarkers of kidney damage-related analytes
- Identifies the risk of CKD development / progression following an AKI episode
- Unique combination of analytes ensures better sensitivity and accuracy compared to traditional serum creatinine measurement
- Utilised widely in safety endpoint monitoring or drug-related renal toxicity during clinical trials
- The Randox CKD arrays utilises biomarkers to profile slow verus rapid CKD progression
- Biochip Technology effectively diagnoses early CKD, differentiates between stages and predicts a decline in a patient’s renal function
Chronic Kidney Disease is an abnormal kidney function and/ or structure, present for a minimum period of 3 months.
Typically diagnosed on the basis of serum creatine concentration, however, currently employed urine biomarkers do not reliably detect the early stages of CKD at which intervention could be more effective. Screening for CKD and any subsequent required treatments may then alter the course of early stage CKD and reduce complications and/or the associated health conditions.
Utilising patented Biochip Technology, the Randox Chronic Kidney Disease (CKD) arrays could improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage.
Randox Chronic Kidney Disease (CKD) Array I (7-plex)
EGF regulates renal cell proliferation, fibrosis and inflammation and is produced in response to renal injury.
IL-8 endothelial-derived chemokine involved in recruiting neutrophils to sites of injury and stimulating their response.
sTNFR1 is used to identify an increase in inflammatory conditions such as CKD.
FABP1 binds long-chain fatty acids, contributing to reducing oxidative stress in the kidneys.
sTNFR2 is used to identify an increase in inflammatory conditions such as CKD.
D-Dimer is a fibrin degradation product, and an index of both coagulation and fibrinolysis.
MIP-1 alpha plays a roles in inflammatory responses at sites of injury or infection.
Randox Chronic Kidney Disease (CKD) Array II (4-plex)
CRP is an acute phase reactant involved in inflammation.
Cystatin C is well recognised marker of kidney filtration dysfunction and injury.
C3a des Arg is a representative of complement component C3a which produces local inflammatory responses.
NGAL is among the current state-of-the-art in CKD biomarkers.
The Evidence Investigator
Meet the Evidence Investigator
The Randox CKD arrays have both been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser.
The CKD array’s would improve patient risk stratification whilst monitoring the effectiveness of treatment. Diagnosis of CKD at early stages will allow earlier intervention for the treatment of kidney disease, and the prevention of further kidney damage. Currently available for RUO.
Want to know more?
Contact us or visit our Investigator Webpage
